These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 14551737)

  • 1. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities.
    Thornton PD; Matutes E; Bosanquet AG; Lakhani AK; Grech H; Ropner JE; Joshi R; Mackie PH; Douglas ID; Bowcock SJ; Catovsky D
    Ann Hematol; 2003 Dec; 82(12):759-65. PubMed ID: 14551737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
    Valgañón M; Giraldo P; Agirre X; Larráyoz MJ; Rubio-Martinez A; Rubio-Felix D; Calasanz MJ; Odero MD
    Br J Haematol; 2005 Apr; 129(1):53-9. PubMed ID: 15801955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
    Willis CR; Goodrich A; Park K; Waselenko JK; Lucas M; Reese A; Diehl LF; Grever MR; Byrd JC; Flinn IW
    Ann Hematol; 2006 May; 85(5):301-7. PubMed ID: 16518606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia.
    Xu W; Miao KR; Hong M; Zhu DX; Fang C; Dong HJ; Wang DM; Cao X; Li JY
    Eur J Cancer; 2010 Aug; 46(12):2145-9. PubMed ID: 20627536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs.
    Morabito F; Filangeri M; Callea I; Sculli G; Callea V; Fracchiolla NS; Neri A; Brugiatelli M
    Haematologica; 1997; 82(1):16-20. PubMed ID: 9107076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
    Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
    Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
    Laurenti L; Tarnani M; De Padua L; Efremov DG; Zini G; Garzia M; Piccirillo N; Chiusolo P; Sorà F; Innocenti I; Sica S; Leone G
    Ann Hematol; 2008 Nov; 87(11):891-8. PubMed ID: 18587576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
    Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T
    Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy.
    Dungarwalla M; Evans SO; Riley U; Catovsky D; Dearden CE; Matutes E
    Haematologica; 2008 Mar; 93(3):475-6. PubMed ID: 18310545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
    Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia.
    Willmore E; Elliott SL; Mainou-Fowler T; Summerfield GP; Jackson GH; O'Neill F; Lowe C; Carter A; Harris R; Pettitt AR; Cano-Soumillac C; Griffin RJ; Cowell IG; Austin CA; Durkacz BW
    Clin Cancer Res; 2008 Jun; 14(12):3984-92. PubMed ID: 18559621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
    Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
    Aydin S; Dührsen U; Nückel H
    Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
    Tóthová E; Kafková A; Fricová M; Guman T; Stecová N
    Neoplasma; 2003; 50(6):433-7. PubMed ID: 14689065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
    Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
    Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells.
    Campàs C; Cosialls AM; Barragán M; Iglesias-Serret D; Santidrián AF; Coll-Mulet L; de Frias M; Domingo A; Pons G; Gil J
    Exp Hematol; 2006 Dec; 34(12):1663-9. PubMed ID: 17157163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
    Aleskog A; Tobin G; Laurell A; Thunberg U; Lindhagen E; Roos G; Nilsson K; Nygren P; Sundström C; Höglund M; Larsson R; Rosenquist R
    Eur J Haematol; 2004 Dec; 73(6):407-11. PubMed ID: 15522062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro chemosensitivity of chronic lymphocytic leukemia B-cells to multidrug regimen (CEOP) compounds using the MTT colorimetric assay.
    Morabito F; Messina G; Oliva B; Ramirez F; Callea V; Brugiatelli M; Nobile F
    Haematologica; 1993; 78(4):213-8. PubMed ID: 8294052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia.
    Forconi F; Fabbri A; Lenoci M; Sozzi E; Gozzetti A; Tassi M; Raspadori D; Lauria F
    Hematol Oncol; 2008 Dec; 26(4):247-51. PubMed ID: 18642397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group.
    Robak T; Blonski JZ; Wawrzyniak E; Gora-Tybor J; Palacz A; Dmoszynska A; Konopka L; Warzocha K; Jamroziak K
    Cancer; 2009 Jan; 115(1):94-100. PubMed ID: 19025975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.